| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
|
Peters, S.
|
|
|
33 |
1 |
p. 67-79
|
artikel
|
| 2 |
Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’
|
Dimopoulos, M.A.
|
|
|
33 |
1 |
p. 117
|
artikel
|
| 3 |
Corrigendum to ‘43P The effect of quercetin and doxorubicin treatment on the proliferative capacity of tumour cells’
|
Alexandru, D.M.
|
|
|
33 |
1 |
p. 118
|
artikel
|
| 4 |
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
|
Federico, L.
|
|
|
33 |
1 |
p. 42-56
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
33 |
1 |
p. iii
|
artikel
|
| 6 |
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
|
Nelli, F.
|
|
|
33 |
1 |
p. 107-108
|
artikel
|
| 7 |
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
|
Dimitriou, F.
|
|
|
33 |
1 |
p. 99-106
|
artikel
|
| 8 |
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ☆
|
Casali, P.G.
|
|
|
33 |
1 |
p. 20-33
|
artikel
|
| 9 |
Hesitancy around low-dose CT screening for lung cancer
|
Dickson, J.L.
|
|
|
33 |
1 |
p. 34-41
|
artikel
|
| 10 |
Improved breast cancer histological grading using deep learning
|
Wang, Y.
|
|
|
33 |
1 |
p. 89-98
|
artikel
|
| 11 |
Innovation at life’s end: a moment for hope
|
Corn, B.W.
|
|
|
33 |
1 |
p. 15-16
|
artikel
|
| 12 |
Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer
|
Chow, A.
|
|
|
33 |
1 |
p. 4-5
|
artikel
|
| 13 |
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
|
Novello, S.
|
|
|
33 |
1 |
p. 57-66
|
artikel
|
| 14 |
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
|
Saini, K.S.
|
|
|
33 |
1 |
p. 6-12
|
artikel
|
| 15 |
PET imaging for cancer immunotherapy: the Immuno-PET
|
Menzies, A.M.
|
|
|
33 |
1 |
p. 13-14
|
artikel
|
| 16 |
SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment
|
Figueiredo, J.C.
|
|
|
33 |
1 |
p. 109-111
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
33 |
1 |
p. i-ii
|
artikel
|
| 18 |
Thanks to referees 2021
|
|
|
|
33 |
1 |
p. 1-3
|
artikel
|
| 19 |
The enduring decision-making role of the surgeon in the multidisciplinary management of GIST
|
Swallow, C.J.
|
|
|
33 |
1 |
p. 17-19
|
artikel
|
| 20 |
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
|
Kelley, R.K.
|
|
|
33 |
1 |
p. 114-116
|
artikel
|
| 21 |
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
|
Lu, S.
|
|
|
33 |
1 |
p. 112-113
|
artikel
|
| 22 |
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
|
Kok, I.C.
|
|
|
33 |
1 |
p. 80-88
|
artikel
|
Tijdschrift beschrijving